Synaptic abnormalities are a cardinal feature of Alzheimer's disease (AD) that are known to
arise as the disease progresses. A growing body of evidence suggests that pathological …

Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

Alzheimer's disease (AD) is characterized by extracellular aggregates of amyloid β peptides,
intraneuronal tau aggregates, and neuronal death. This pathology triggers activation of …

Alzheimer's disease (AD) is the most common form of dementia worldwide. β-amyloid
peptide (Aβ) is currently assumed to be the main cause of synaptic dysfunction and cognitive …

The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and
pathogens from entering the brain. At the same time, the BBB regulates transport of …

Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially
driven by genetics. To identify LOAD risk loci, we performed a large genome-wide …

In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …

Genome-wide association studies and functional genomics studies have linked specific cell
types, genes, and pathways to Alzheimer's disease (AD) risk. In particular, AD risk alleles …

Alzheimer disease is a progressive neurodegenerative disorder, mainly affecting older
people, which severely impairs patients' quality of life. In the recent years, the number of …

Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of
evidence from laboratories and clinics worldwide support the concept that an imbalance …